Ovarian Cancer

Gynecologic Oncology Group to conduct phase III trial of Xyotax

Published in Cancer Weekly, December 10th, 2002

Cell Therapeutics, Inc., (CTI) (CTIC) and the Gynecologic Oncology Group (GOG) announced that the GOG will conduct a phase III trial of Xyotax in front-line treatment of ovarian cancer.

The trial is expected to begin in 2003 and to enroll approximately 1,000 patients over 12 months.

"The mission of the GOG is to improve the lives and outcomes of patients with gynecologic cancers. While we have made significant progress in prolonging the lives of women with ovarian cancer, one of our biggest challenges is to improve their quality of life, given the serious side effects of current chemotherapy," noted Larry J. Copeland, MD, Department of Obstetrics...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-12-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry